Skip to main content

Table 4 Comparison of the findings of the current study with those of previous studies associated with advanced mucinous ovarian carcinoma

From: Comparison of stage III mucinous and serous ovarian cancer: a case-control study

Author Number of women with MOC Stage of disease Extent of residual disease Median PFS (months) Media OS (months)
Hess, 2004 [18] 27 III, IV optimal or suboptimal 5.7 12.0
Pectasides, 2005 [27] 47 III, IV optimal or suboptimal 11.8 33.2
Winter, 2007 [19] 34 III optimal or suboptimal 10.5 14.8
Bamias, 2010 [8] 24 III, IV optimal or suboptimal NR 15.4
Mackay, 2010 [20] 264 III, IV optimal or suboptimal 7.6 14.6
Bamias, 2012 [21] 21 III, IV optimal or suboptimal NR 15.0
Karabuk, 2013 [14] 50 III, IV optimal or suboptimal 7.0 35.0
Current study 81 III maximal or optimal 18.0 45.0
  1. Abbreviations: MOC mucinous ovarian carcinoma, PFS progression-free survival, OS overall survival, NR not reported